Skip to main content

Advertisement

SpringerLink
Log in

Development of anti-angiogenic erlotinib liposomal formulation for pulmonary hypertension: a QbD approach

  • Original Article
  • Published:
Drug Delivery and Translational Research Aims and scope Submit manuscript

Abstract

Pulmonary arterial hypertension (PAH) is the increase in mean pulmonary arterial pressure (> 25 mmHg). The development of the non-reversible plexiform lesions on the arterial walls of the pulmonary arteries has evolved as the reason to increase the pressure. The current treatments are directed towards the vasodilation of the pulmonary arteries via the endothelin, prostacyclin, and NO pathways which provides symptomatic relief. Deeper understanding of the disease leads to the various pathophysiological targets that play an important role in the development of PAH. Out of these, the angiogenetic mechanism of the pulmonary arterial smooth muscle cells has been proved to play an important role in PAH. Targeted therapies by anti-proliferative drugs may lead to the efficient treatment strategies to the root cause of PAH. Erlotinib, a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR), has shown promising results in clinical trials of PAH. The objective of the work has been the development of liposomal formulation of anti-proliferative drug, erlotinib HCl, via Quality by Design (QbD) approach. The liposomal formulation was developed using thin-film hydration technique and characterised for various physicochemical parameters, like particle size, % entrapment efficiency, DSC, FTIR, pXRD, and TEM. In the drug release study, the formulation showed sustained release of erlotinib over 24 h in simulated lung fluid pH 7.4. This developed formulation was evaluated in zebrafish tail fin regeneration assay for its anti-angiogenetic activity. The liposomal formulation inhibited the tail fin regeneration for 14 days indicating anti-angiogenetic activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13

Similar content being viewed by others

References

  1. Sutendra G, Michelakis ED. The metabolic basis of pulmonary arterial hypertension. Cell Metab. 2014;19(4):558–73.

    Article  CAS  PubMed  Google Scholar 

  2. George MG, Schieb LJ, Ayala C, Talwalkar A, Levant S. Pulmonary hypertension surveillance United States, 2001 to 2010. Chest. 2014;146(2):476–807.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Duarte JD, Hanson RL, Machado RF. Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Futur Cardiol. 2013;9(3):335–49.

    Article  CAS  Google Scholar 

  4. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51(16):1527–38.

    Article  PubMed  Google Scholar 

  5. McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976–97.

    Article  PubMed  Google Scholar 

  6. McLaughlin VVMD, McGoon MDMD. Pulmonary arterial hypertension. Circ. 2006;114:1417–31.

    Article  Google Scholar 

  7. Smythe W, Mcilleron H, Merle C, Horton J, Smith P, Simonsson, USH. A semi-mechanistic pharmacokinetic auto-induction model for the characterisation of rifampicin pharmacokinetics in African pulmonary tuberculosis infected adults. Poster Abstracts page 2010, 39.

  8. Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev. 2012;64(3):583–620.

    Article  CAS  PubMed  Google Scholar 

  9. Sakao S, Tatsumi K, Voelkel NF. Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2010;43(6):629–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Vaidya B, Gupta V. Novel therapeutic approaches for pulmonary arterial hypertension: unique molecular targets to site-specific drug delivery. J Control Release. 2015;211:118–33.

    Article  CAS  PubMed  Google Scholar 

  11. Galie N, Ghofrani A-H. New horizons in pulmonary arterial hypertension therapies. Eur Respir Rev. 2013;22(130):503–14.

    Article  PubMed  Google Scholar 

  12. Chakraborty C, Hsu CH, Wen ZH, Lin CS, Agoramoorthy G. Zebrafish: a complete animal model for in vivo drug discovery and development. Curr Drug Metab. 2009;10(2):116–24.

    Article  CAS  PubMed  Google Scholar 

  13. Rubinstein AL. Zebrafish: from disease modeling to drug discovery. Curr Opin Drug Di De. 2003;6:218–23.

    CAS  Google Scholar 

  14. Chávez MN, Aedo G, Fierro FA, Allende ML, Egaña JT. Zebrafish as an emerging model organism to study angiogenesis in development and regeneration. Front Physiol. 2016;7(MAR):1–15.

    Google Scholar 

  15. Xu H, He C, Liu Y, Jiang J, Ma T. Novel therapeutic modalities and drug delivery—erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. Artif Cell Nanomed B. 2018;46(8):1902–7.

    CAS  Google Scholar 

  16. Nimmano N, Somavarapu S, Taylor KM. Aerosol characterisation of nebulised liposomes co-loaded with erlotinib and genistein using an abbreviated cascade impactor method. Int J Pharm. 2018;542(1–2):8–17.

    Article  CAS  PubMed  Google Scholar 

  17. Pitsiou G, Zarogoulidis P, Petridis D, Kioumis I, Lampaki S, Organtzis J, et al. Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment. Drug Des Dev Ther. 2014;8:1753–63.

    CAS  Google Scholar 

  18. Xu X, Khan MA, Burgess DJ. A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm. 2012;423(2):543–53.

    Article  CAS  PubMed  Google Scholar 

  19. Sylvester B, Porfire A, Muntean DM, Vlase L, Lupuţ L, Licarete E, et al. Optimization of prednisolone-loaded long-circulating liposomes via application of quality by design (QbD) approach. J Lipos Res. 2018;28(1):49–61.

    Article  CAS  Google Scholar 

  20. ICH. Pharmaceutical development Q8. ICH Harmon Tripart Guidel. 2009;8(August):1–28.

    Google Scholar 

  21. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. ICH Expert Working Group. Quality risk management Q9. ICH Harmon Tripart Guidel. 2005;(November):1–23.

  23. Roy B, Guha P, Bhattarai R, Nahak P, Karmakar G, Chettri P, et al. Influence of lipid composition, pH, and temperature on physicochemical properties of liposomes with curcumin as model drug. J Oleo Sci. 2016;65(5):399–411.

    Article  CAS  PubMed  Google Scholar 

  24. Mahmoud M, Labiba N, Khalil EK, Khalafallah N. Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. Acta Pol Pharm Drug Res. 2005;62(5):369–79.

    Google Scholar 

  25. Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul. 1995;12(3):229–46.

    Article  CAS  PubMed  Google Scholar 

  26. Makrilia N, Lappa T, Xyla V, Nikolaidis I, Syrigos K. The role of angiogenesis in solid tumours: an overview. Eur J Intern Med. 2009;20(7):663–71.

    Article  CAS  PubMed  Google Scholar 

  27. Poss KD, Keating MT, Nechiporuk A. Tales of regeneration in zebrafish. Dev Dynam. 2003;226(2):202–10.

    Article  Google Scholar 

  28. Schuermann A, Helker CSM, Herzog W. Angiogenesis in zebrafish. Semin Cell Dev Biol. 2014;31:106–14.

    Article  CAS  PubMed  Google Scholar 

  29. Eyries M, Siegfried G, Ciumas M, Montagne K, Agrapart M, Lebrin F, et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ Res. 2008;103(4):432–40.

    Article  CAS  PubMed  Google Scholar 

  30. Rathinasamy VS, Paneerselvan N, Jagadeeshan S, Malathi R. Hypoxia induced angiogenesis and upregulation of VEGF: an in vivo study using zebrafish model. Int J Sci Eng Res. 2015;6(6):831–9.

    Google Scholar 

Download references

Ethical approval and animal care and use

All institutional and national guidelines for care and use of laboratory animals were followed.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Parekh Marg, Matunga, Mumbai, 400 019, India

    Sagar Dhoble & Vandana Patravale

Authors
  1. Sagar Dhoble
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vandana Patravale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vandana Patravale.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhoble, S., Patravale, V. Development of anti-angiogenic erlotinib liposomal formulation for pulmonary hypertension: a QbD approach. Drug Deliv. and Transl. Res. 9, 980–996 (2019). https://doi.org/10.1007/s13346-019-00641-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13346-019-00641-2

Keywords

Search

Navigation